标题
T-cell-independent Antitumor Effects of CD40 Ligation
作者
关键词
-
出版物
INTERNATIONAL REVIEWS OF IMMUNOLOGY
Volume 31, Issue 4, Pages 267-278
出版商
Informa UK Limited
发表日期
2012-07-18
DOI
10.3109/08830185.2012.698337
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.
- (2017) P. W. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors
- (2011) F. Aranda et al. CANCER RESEARCH
- Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
- (2011) T. S. Lewis et al. CLINICAL CANCER RESEARCH
- Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
- (2011) Q. Li et al. CLINICAL CANCER RESEARCH
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- CD40-mediated cell death requires TRAF6 recruitment
- (2011) Malek Jundi et al. IMMUNOBIOLOGY
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
- (2011) B. Burington et al. Science Translational Medicine
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial
- (2010) P.-U. Malmstrom et al. CLINICAL CANCER RESEARCH
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
- (2010) Ilia N. Buhtoiarov et al. IMMUNOLOGY
- CD40-activated B cells contribute to mesothelioma tumor regression
- (2010) Connie Jackaman et al. IMMUNOLOGY AND CELL BIOLOGY
- CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
- (2010) Anusha Kalbasi et al. JOURNAL OF IMMUNOTHERAPY
- Enhanced T-cell-independent Antitumor Effect of Cyclophosphamide Combined With Anti-CD40 mAb and CpG in Mice
- (2010) Erik E. Johnson et al. JOURNAL OF IMMUNOTHERAPY
- Regression of Established AB1 Murine Mesothelioma Induced by Peritumoral Injections of CpG Oligodeoxynucleotide Either Alone or in Combination with Poly(I:C) and CD40 Ligand Plasmid DNA
- (2010) Geoffrey W. Stone et al. Journal of Thoracic Oncology
- Biology and Clinical Applications of CD40 in Cancer Treatment
- (2010) Ester Fonsatti et al. SEMINARS IN ONCOLOGY
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
- (2009) P.-Y. Pan et al. CANCER RESEARCH
- In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
- (2009) U. K. Scarlett et al. CANCER RESEARCH
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy
- (2009) S. A. Broomfield et al. JOURNAL OF IMMUNOLOGY
- Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
- (2009) Erica L Carpenter et al. Journal of Translational Medicine
- Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma
- (2009) Geoffrey W. Stone et al. PLoS One
- The role of CD40 and CD154/CD40L in dendritic cells
- (2009) Daphne Y. Ma et al. SEMINARS IN IMMUNOLOGY
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors
- (2008) Alexander L. Rakhmilevich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
- (2008) Connie Jackaman et al. INTERNATIONAL IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More